The committee must recommend to the department: therapeutic classes of drugs that should be subject to enhanced prior approval program requirements; guidelines to determine whether a drug is subject to enhanced prior approval to include clinical effectiveness, physician impact, hospital and other costs, and safety profile; and specific drugs within each therapeutic class to be subject to enhanced